Biofrontera Inc. announced preliminary unaudited revenue results for the fourth quarter ended December 31, 2025, expecting revenues between $17.0 million and $17.5 million. This represents the highest quarterly revenue in the company’s history and a year-over-year growth of approximately 35% to 39%, driven by strong sales execution of Ameluz®. For the full year 2025, Biofrontera anticipates revenues in the range of $41.5 million to $42.0 million, reflecting double-digit growth of approximately 11% to 13% compared to the previous year. The company attributes these results to continued growth of its Ameluz® photodynamic therapy product and a pricing adjustment introduced in December.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biofrontera Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9624735) on January 13, 2026, and is solely responsible for the information contained therein.